Italia markets closed

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
6,03+0,42 (+7,49%)
Alla chiusura: 01:00PM EST
5,60 -0,43 (-7,13%)
Dopo ore: 04:22PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente5,61
Denaro3,78 x 1800
Lettera6,35 x 1100
Min-Max giorno5,66 - 6,14
Intervallo di 52 settimane1,45 - 7,92
Media Volume185.531
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-2,01
Prossima data utili09 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A7,00
  • GlobeNewswire

    Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

    Terns plans to initiate U.S. clinical trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in second half of 2023Positive data from Phase 1 trial of TERN-501 (THR-β agonist) in NASH presented at AASLD 2022, with top-line data from Phase 2a DUET trial expected in second half of 2023IND-enabling activities for TERN-601 (oral GLP-1R agonist) remain on track with plans to initiate first-in-human clinical trial in obesity in 2023Cash and equivalents of $187 million provides runway into 2025, incl

  • GlobeNewswire

    Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022

    Data demonstrated treatment with TERN-501 resulted in time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker linked to NASH histologic efficacy Phase 2a DUET trial evaluating TERN-501 alone and in combination with TERN-101, the first trial assessing both THR-β and FXR agonists in NASH, is ongoing FOSTER CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company

  • GlobeNewswire

    Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022

    FOSTER CITY, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that the company will present two abstracts regarding its investigational therapies TERN-501, a THR-β agonist, and TERN-101, an FXR agonist, in clinical dev